Emotional Dysregulation with Explosive Outbursts
November 9, 2022, 7:30-8:30 AM
Via Zoom Webinar!
Attention Section 90 Providers: Updated Changes for Billing Topical Fluoride Varnish, CR 111959
In a July 22, 2022, e-message the Department indicated Current Procedural Terminology (CPT) code 99188 (application of topical fluoride varnish by a physician or other qualified health professional) would be reimbursed the same rate as Current Dental Terminology (CDT) code D1206, Topical Application of Fluoride Var
Resolved -- Claims Export Issue on the Health PAS Portal, CR 108606
Some providers have reported errors when attempting to export claims to Excel from the Health PAS Online Portal. This was due to an issue where wide date parameters in the claims search were timing out during the export to Excel process. This issue has been resolved.
HOPE Program Helps Maine Families Achieve Economic Independence
Oct 10, 2022
The Higher Opportunities for Pathways to Employment (HOPE) program, offered through the Maine Department of Health and Human Services (DHHS) Office for Family Independence (OFI), supports Maine parents in pursuing meaningful careers while helping to address Maine’s workforce needs.
Use of Palivizumab Prophylaxis to Prevent Hospitalization from Severe RSV Infection
The Office of MaineCare Services (OMS), in coordination with their Pharmacy Benefits Manager Change Healthcare (CHC), review data from the National Respiratory and Enteric Virus Surveillance System (NREVSS) to track the epidemic season for Respiratory Syncytial Virus (RSV). Palivizumab is indicated for the prevention of serious lower respiratory tract disease caused by RSV in infants. Peak RSV activity typically occurs between November and March.
Use of Palivizumab Prophylaxis to Prevent Hospitalization from Severe RSV Infection
The Office of MaineCare Services (OMS), in coordination with their Pharmacy Benefits Manager Change Healthcare (CHC), review data from the National Respiratory and Enteric Virus Surveillance System (NREVSS) to track the epidemic season for Respiratory Syncytial Virus (RSV). Palivizumab is indicated for the prevention of serious lower respiratory tract disease caused by RSV in infants. Peak RSV activity typically occurs between November and March.
Use of Palivizumab Prophylaxis to Prevent Hospitalization from Severe RSV Infection
The Office of MaineCare Services (OMS), in coordination with their Pharmacy Benefits Manager Change Healthcare (CHC), review data from the National Respiratory and Enteric Virus Surveillance System (NREVSS) to track the epidemic season for Respiratory Syncytial Virus (RSV). Palivizumab is indicated for the prevention of serious lower respiratory tract disease caused by RSV in infants. Peak RSV activity typically occurs between November and March.
URGENT NOTICE: Abrupt Service Disruption in Southern Maine
The Maine Prescription Monitoring Program (PMP) is notifying all pharmacists and pharmacy staff of an abrupt service disruption event affecting several hundred patients in southern Maine. A pain and addiction medicine clinic in this region has been affected by federal law enforcement action, leaving patients without access to their usual care.
URGENT NOTICE: Abrupt Service Disruption in Southern Maine
The Maine Prescription Monitoring Program (PMP) is notifying all health care providers and institutions of an abrupt service disruption affecting several hundred patients in southern Maine. A pain and addiction medicine clinic in this region has been affected by federal law enforcement action, leaving patients without access to their usual care.
MaineCare Notice of Agency State Plan Submission, 1915(k) Community First Choice State Plan Option
This is a duplicate posting of an e-message that was sent yesterday, updated to correct a systems issue that impacted a few of the links within the message.